Zobrazeno 1 - 10 of 188 pro vyhledávání: '"Chateau MC"'
1
Akademický článek
Prognostic value of tertiary lymphoid structures in triple-negative breast cancer: integrated analysis with the tumor microenvironment and clinicopathological features.
Autor: Boissière-Michot F; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France., Chateau MC; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France., Thézenas S; Biometry Department, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France., Lafont V; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier, France., Crapez E; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier, France., Sharma P; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier, France., Bobrie A; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier, France.; Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France., Roger P; Pathology Department, Nîmes University Hospital, Nîmes, France., Guiu S; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier, France.; Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France., Jacot W; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier, France.; Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.; Faculty of Medicine, Montpellier University, Montpellier, France.
Publikováno v: Frontiers in immunology [Front Immunol] 2024 Dec 12; Vol. 15, pp. 1507371. Date of Electronic Publication: 2024 Dec 12 (Print Publication: 2024).
Zobrazit plný text záznamu
2
Akademický článek
A novel Fc-engineered cathepsin D-targeting antibody enhances ADCC, triggers tumor-infiltrating NK cell recruitment, and improves treatment with paclitaxel and enzalutamide in triple-negative breast cancer.
Autor: Desroys du Roure P; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Lajoie L; Université de Tours - INRAE, UMR1282, Infectiologie et Santé Publique (ISP), équipe BioMédicaments Anti-Parasitaires (BioMAP), Tours, France., Mallavialle A; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Alcaraz LB; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Mansouri H; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; RHEM, IRCM, Montpellier, France., Fenou L; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Garambois V; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Rubio L; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., David T; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Coenon L; IRMB, University of Montpellier, INSERM, CNRS, CHU Montpellier, Montpellier, France., Boissière-Michot F; Translational Research Unit, ICM, Montpellier, France., Chateau MC; Translational Research Unit, ICM, Montpellier, France., Ngo G; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Jarlier M; Biometry Department, ICM, Montpellier, France., Villalba M; IRMB, University of Montpellier, INSERM, CNRS, CHU Montpellier, Montpellier, France.; Institut du Cancer Avignon-Provence Sainte Catherine, Avignon, France., Martineau P; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Laurent-Matha V; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France., Roger P; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; Department of Pathology, CHU Nîmes, Nimes, France., Guiu S; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; Department of Medical Oncology, ICM, Montpellier, France., Chardès T; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; CNRS, Centre national de la recherche Scientifique, Paris, F-75016, France., Gros L; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France.; CNRS, Centre national de la recherche Scientifique, Paris, F-75016, France., Liaudet-Coopman E; IRCM, INSERM U1194, University of Montpellier, ICM, Montpellier, France emmanuelle.liaudet-coopman@inserm.fr.
Publikováno v: Journal for immunotherapy of cancer [J Immunother Cancer] 2024 Jan 30; Vol. 12 (1). Date of Electronic Publication: 2024 Jan 30.
Zobrazit plný text záznamu
3
Akademický článek
Prognostic Relevance of Tumor-Infiltrating Immune Cells in Cervix Squamous Cell Carcinoma.
Autor: Wild CM; Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany.; Department of Data Management and Clinical Decision Support, Faculty of Medicine, University of Augsburg, 86159 Augsburg, Germany., Garrido F; Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany., Dannecker C; Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany., Köpke MB; Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany., Chateau MC; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, 208 rue des Apothicaires, F-34298 Montpellier, France., Boissière-Michot F; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, 208 rue des Apothicaires, F-34298 Montpellier, France., Heidegger HH; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany., Vattai A; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany., Kessler M; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany., Jeschke U; Department of Obstetrics and Gynecology, University Hospital Augsburg, Stenglinstrasse 2, 86156 Augsburg, Germany.; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, Marchioninistraße 15, 81377 Munich, Germany., Cavaillès V; Institut de Recherche en Cancérologie de Montpellier (IRCM), INSERM U1194, Université Montpellier, CNRS, F-34298 Montpellier, France.
Publikováno v: Cancers [Cancers (Basel)] 2023 Oct 12; Vol. 15 (20). Date of Electronic Publication: 2023 Oct 12.
Zobrazit plný text záznamu
4
Akademický článek
Correlation of the TIGIT-PVR immune checkpoint axis with clinicopathological features in triple-negative breast cancer.
Autor: Boissière-Michot F; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France., Chateau MC; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France., Thézenas S; Biometrics Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France., Guiu S; Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier, France., Bobrie A; Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier, France., Jacot W; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.; Department of Medical Oncology, Montpellier Cancer Institute Val d'Aurelle, Montpellier, France.; Institut de Recherche en Cancérologie de Montpellier (IRCM), Inserm U1194, Montpellier, France.; Faculty of Medicine, Montpellier University, Montpellier, France.
Publikováno v: Frontiers in immunology [Front Immunol] 2022 Dec 05; Vol. 13, pp. 1058424. Date of Electronic Publication: 2022 Dec 05 (Print Publication: 2022).
Zobrazit plný text záznamu
5
Akademický článek
Prognostic Relevance of Nuclear Receptors in Relation to Peritumoral Inflammation and Tumor Infiltration by Lymphocytes in Breast Cancer.
Autor: Köpke MB; Department of Obstetrics & Gynecology, University Hospital Augsburg, 86156 Augsburg, Germany., Chateau MC; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, 208 rue des Apothicaires, F-34298 Montpellier, France., Boissière-Michot F; Translational Research Unit, Montpellier Cancer Institute Val d'Aurelle, 208 rue des Apothicaires, F-34298 Montpellier, France., Schneider M; Department of Obstetrics & Gynecology, University Hospital Augsburg, 86156 Augsburg, Germany., Garrido F; Department of Obstetrics & Gynecology, University Hospital Augsburg, 86156 Augsburg, Germany., Zati-Zehni A; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany., Vilsmaier T; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany., Kessler M; Department of Obstetrics and Gynecology, University Hospital, LMU Munich, 81377 Munich, Germany., Ditsch N; Department of Obstetrics & Gynecology, University Hospital Augsburg, 86156 Augsburg, Germany., Cavaillès V; IRCM-Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université Montpellier, Parc Euromédecine, 208 rue des Apothicaires, F-34298 Montpellier, France., Jeschke U; Department of Obstetrics & Gynecology, University Hospital Augsburg, 86156 Augsburg, Germany.
Publikováno v: Cancers [Cancers (Basel)] 2022 Sep 20; Vol. 14 (19). Date of Electronic Publication: 2022 Sep 20.
Zobrazit plný text záznamu
6
Akademický článek
Nationwide incidence of sarcomas and connective tissue tumors of intermediate malignancy over four years using an expert pathology review network.
Autor: de Pinieux G; Department of pathology, CHU de Tours, Tours, France., Karanian M; Department of Biopathology, Centre Léon Bérard, Lyon, France., Le Loarer F; Department of Biopathology, Institut Bergonié, Bordeaux, France., Le Guellec S; Department of Biopathology, Institut Claudius Regaud et Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse, France., Chabaud S; Department of Biopathology, Centre Léon Bérard, Lyon, France., Terrier P; Department of Biopathology, Gustave Roussy, Villejuif, France., Bouvier C; Department of pathology, La Timone University Hospital, Marseille, France., Batistella M; Pathology Department, Saint-Louis Hospital, AP-HP, Université de Paris, Paris, France., Neuville A; Department of Biopathology, Institut Bergonié, Bordeaux, France., Robin YM; Pôle de Biologie-Pathologie-Génétique Centre Oscar Lambret, & Institut de Pathologie entre Oscar Lambret & CHU Lille, Lille, France., Emile JF; Department of Biopathology, Hopital Ambroise Paré, Boulogne, France., Moreau A; Department of Pathology, Department of Orthopedy CHU Nantes, Nantes, France., Larousserie F; Department of Biopathology, Hôpital Cochin-Saint-Vincent de Paul, Paris, France., Leroux A; Department of Biopathology, Institut de Cancérologie de Lorraine-Alexis Vautrin, Vandoeuvre-lès-Nancy, France., Stock N; Department of Biopathology, Eugene Marquis Comprehensive Cancer Center & CHU Rennes, Rennes, France., Lae M; Department of Biopathology, Eugene Marquis Comprehensive Cancer Center & CHU Rennes, Rennes, France.; Department of Biopathology, Institut Curie, Paris, France., Collin F; Department of Biopathology, Centre Georges François Leclerc, Dijon, France., Weinbreck N; Medipath, Frejus, France., Aubert S; Pôle de Biologie-Pathologie-Génétique Centre Oscar Lambret, & Institut de Pathologie entre Oscar Lambret & CHU Lille, Lille, France., Mishellany F; Department of Biopathology, Centre Jean Perrin, Clermont-Ferrand, France., Charon-Barra C; Department of Biopathology, Centre Georges François Leclerc, Dijon, France., Croce S; Department of Biopathology, Institut Bergonié, Bordeaux, France., Doucet L; Department of pathology, CHRU Brest, Brest, France., Quintin-Rouet I; Department of pathology, CHRU Brest, Brest, France., Chateau MC; Department of Biopathology, Institut de Cancérologie de Montpellier & CHU Montpellier, Montpellier, France., Bazille C; Department of Biopathology, Centre Francois Baclesse, Caen, France., Valo I; Department of Pathology, Institut de Cancerologie de l'Ouest, Angers, France., Chetaille B; Medipath, Frejus, France., Ortonne N; Department of Biopathology, Hopital Henri Mondor, Creteil, France., Brouchet A; Department of Biopathology, Institut Claudius Regaud et Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse, France., Rochaix P; Department of Biopathology, Institut Claudius Regaud et Institut Universitaire du Cancer de Toulouse-Oncopôle, Toulouse, France., Demuret A; Department of pathology, CHU de Tours, Tours, France., Ghnassia JP; Department of Biopathology, Centre Paul Strauss, Strasbourg, France., Mescam L; Department of Biopathology, Institut Paoli Calmettes, Marseille, France., Macagno N; Department of pathology, La Timone University Hospital, Marseille, France., Birtwisle-Peyrottes I; Department of Biopathology, Centre Antoine-Lacassagne, Nice, France., Delfour C; Department of Biopathology, Institut de Cancérologie de Montpellier & CHU Montpellier, Montpellier, France., Angot E; Department of Biopathology, Eugene Marquis Comprehensive Cancer Center & CHU Rennes, Rennes, France., Pommepuy I; Department of Biopathology, CHU Limoges, Limoges, France., Ranchere D; Department of Biopathology, Centre Léon Bérard, Lyon, France., Chemin-Airiau C; Department of Biopathology, Centre Léon Bérard, Lyon, France., Jean-Denis M; Department of Biopathology, Centre Léon Bérard, Lyon, France., Fayet Y; Department of Biopathology, Centre Léon Bérard, Lyon, France., Courrèges JB; Department of Biopathology, Institut Bergonié, Bordeaux, France., Mesli N; Department of Biopathology, Institut Bergonié, Bordeaux, France., Berchoud J; Department of Pathology, Department of Orthopedy CHU Nantes, Nantes, France., Toulmonde M; Department of Biopathology, Institut Bergonié, Bordeaux, France., Italiano A; Department of Biopathology, Institut Bergonié, Bordeaux, France., Le Cesne A; Department of Biopathology, Centre Léon Bérard, Lyon, France., Penel N; Pôle de Biologie-Pathologie-Génétique Centre Oscar Lambret, & Institut de Pathologie entre Oscar Lambret & CHU Lille, Lille, France., Ducimetiere F; Department of Biopathology, Centre Léon Bérard, Lyon, France., Gouin F; Department of Biopathology, Centre Léon Bérard, Lyon, France., Coindre JM; Department of Biopathology, Institut Bergonié, Bordeaux, France., Blay JY; Department of Biopathology, Centre Léon Bérard, Lyon, France.; Department of Medicine of Centre Leon Berard, University Claude Bernard Lyon I, Lyon, France.; Headquarters, Unicancer, Paris, France.
Publikováno v: PloS one [PLoS One] 2021 Feb 25; Vol. 16 (2), pp. e0246958. Date of Electronic Publication: 2021 Feb 25 (Print Publication: 2021).
Zobrazit plný text záznamu
7
Akademický článek
Targeting MDM2-dependent serine metabolism as a therapeutic strategy for liposarcoma.
Autor: Cissé MY; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France., Pyrdziak S; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France., Firmin N; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France.; Institut régional du Cancer Montpellier, Montpellier F-34298, France., Gayte L; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France., Heuillet M; TBI, Université de Toulouse, CNRS, INRA, INSA, Toulouse F-31400, France.; MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse F-31077, France., Bellvert F; TBI, Université de Toulouse, CNRS, INRA, INSA, Toulouse F-31400, France.; MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse F-31077, France., Fuentes M; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France., Delpech H; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France., Riscal R; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France., Arena G; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France., Chibon F; INSERM UMR 1037, Centre de Recherche en Cancérologie de Toulouse, Université Paul Sabatier Toulouse-III, Toulouse F-31100, France., Le Gellec S; INSERM UMR 1037, Centre de Recherche en Cancérologie de Toulouse, Université Paul Sabatier Toulouse-III, Toulouse F-31100, France.; Department of Pathology, Institut Claudius Regaud, IUCT-Oncopole, Toulouse F-31100, France., Maran-Gonzalez A; Institut régional du Cancer Montpellier, Montpellier F-34298, France., Chateau MC; Institut régional du Cancer Montpellier, Montpellier F-34298, France., Theillet C; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France., Carrere S; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France.; Institut régional du Cancer Montpellier, Montpellier F-34298, France., Portais JC; TBI, Université de Toulouse, CNRS, INRA, INSA, Toulouse F-31400, France.; MetaToul-MetaboHUB, National Infrastructure of Metabolomics and Fluxomics, Toulouse F-31077, France.; Université Paul Sabatier, Université de Toulouse, Toulouse F-31062, France., Le Cam L; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France. laetitia.linares@inserm.fr laurent.lecam@inserm.fr.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France., Linares LK; IRCM, Institut de Recherche en Cancérologie de Montpellier, INSERM U1194, Université de Montpellier, Institut régional du Cancer de Montpellier, Montpellier F-34298, France. laetitia.linares@inserm.fr laurent.lecam@inserm.fr.; Equipe Labélisée par la Ligue contre le Cancer, Paris F-75013, France.
Publikováno v: Science translational medicine [Sci Transl Med] 2020 Jun 10; Vol. 12 (547).
Zobrazit plný text záznamu
8
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
9
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.
10
Akademický článek
Tento výsledek nelze pro nepřihlášené uživatele zobrazit.
K zobrazení výsledku je třeba se přihlásit.

Vyhledávací nástroje:

Upřesnit hledání

Omezení vyhledávání
Plný text Recenzováno Digitální knihovna AV ČR
Zdroje